Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis.

The proportion of dogs achieving clinical remission from skin lesions (CADESI‐04 <10) was numerically higher in the ilunocitinib group compared to the oclacitinib group from D56 onwards (43%–69% versus 37%–64%, respectively), although this difference did not reach statistical significance.

also in 111,027 other papers